Developing a long-lasting treatment for hepatitis B virus
Long-acting Antiviral Treatment for HBV
This study is working on a new monthly injection for people with hepatitis B that could help keep the virus under control without the need for daily pills, making it easier for patients to stick to their treatment and stay healthy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10851197 on NIH RePORTER |
What this research studies
This research focuses on creating a long-acting antiviral therapy for hepatitis B virus (HBV) that can provide sustained viral suppression. Current treatments require daily oral medication, which can lead to pill fatigue and inconsistent drug levels, increasing the risk of liver cancer. By leveraging existing antiviral drugs and transforming them into a long-acting injectable form, the research aims to improve treatment adherence and outcomes for patients with HBV, including those co-infected with HIV. The goal is to develop a therapy that can be administered monthly, reducing the burden of daily medication.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with chronic hepatitis B virus infection, particularly those experiencing difficulties with daily oral antiviral medications.
Not a fit: Patients who are not infected with hepatitis B virus or those who are not experiencing complications from their current treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the quality of life for patients with HBV by reducing the need for daily pills and providing more consistent viral control.
How similar studies have performed: Previous research has shown success with long-acting antiviral therapies in HIV treatment, indicating potential for similar advancements in HBV treatment.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Ho, Rodney J.y. — University of Washington
- Study coordinator: Ho, Rodney J.y.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.